Clinical parameters | KORA S4 | KORA S2 | AGES-REFINE | |||
Incident MI | non-MI | Incident MI | non-MI | Incident MI | non-MI | |
n=67 | n=1275 | n=112 | n=549 | n=87 | n=167 | |
Age | 65.5±5.2 | 63.8±5.4 | 59.7±7.5 | 53.6±11.0 | 65.6±8.4 | 65.8±7.9 |
Sex, male, n, % | 52 (77.9) | 623 (48.9) | 85 (75.9) | 271 (49.4) | 53 (61.0) | 103 (62.0) |
BMI, kg/m2 | 29.6±4.8 | 28.3±4.2 | 28.3±3.9 | 27.1±4.0 | 28.1±4.3 | 27.7±5.4 |
Waist-to-hip ratio | 1.0±0.1 | 0.9±0.1 | 0.9±0.1 | 0.9±0.1 | 1.0±0.1* | 1.0±0.1† |
Type 2 diabetes, n (%) | 14 (20.9) | 104 (8.2) | 20 (17.9) | 18 (3.3) | 12 (13.8) | 17 (10.2) |
Smoking | ||||||
Non-smoker, n (%) | 26 (38.2) | 663 (49.7) | 32 (28.6) | 269 (49.0) | 21 (24.1) | 62 (37.1) |
Former smoker, n (%) | 30 (44.1) | 463 (36.3) | 42 (37.5) | 151 (27.5) | 41 (47.1) | 67 (40.1) |
Smoker, n (%) | 12 (17.7) | 117 (13.9) | 38 (33.9) | 129 (23.5) | 25 (28.7) | 39 (23.4) |
Alcohol intake, n (%)‡ | 12 (17.7) | 262 (20.6) | 28 (25) | 153 (27.9) | 9 (18.0)§ | 24 (25.0)¶ |
Physical activity, n (%)** | 16 (23.5) | 560 (43.9) | 30 (26.78) | 208 (37.7) | 26 (30.0) | 69 (42.0) |
Systolic BP, mm Hg | 142.9±24.3 | 135.2±19.8 | 143.8±22.1 | 133.4±18.4 | 138.1±21.5 | 134.4±18.7 |
Total cholesterol, mg/dL | 240.4±38.7 | 244.1±41.2 | 260.7±50.4 | 240.3±43.2 | 228.1±50.3 | 212.9±37.2 |
HDL-C, mg/dL | 53.1±16.8 | 58.9±16.5 | 50.8±15.5 | 58.3±16. 7 | 54.8±17.1 | 61.2±18.5 |
hsCRP, mg/L‡‡ | 2.9±5.2 | 1.7±6.6 | 3.0±6.4 | 1.6±7.8 | 2.3±8.1 | 1.7±4.6 |
Statin user, n (%) | 4 (6.0) | 109 (8.5) | 0 (0) | 3 (0.5) | 8 (9.0) | 25 (15.0) |
*Data available in 37 participants with incident MI.
†Data available in 71 participants.
‡ ≥20 g/day for women; ≥40 g/day for men.
§Data available in 49 participants.
¶Data available in 95 participants.
**>1 hour per week.
‡‡Geometric mean.
Mean ± SD is provided when appropriate.
BMI, body mass index; BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C reactive protein; KORA, Cooperative Health Research in the Region of Augsburg; MI, myocardial infarction; AGES-REFINE, Age, Gene/Environment Susceptibility and the Risk Evaluation For Infarct Estimates-Reykjavik studies.